Drug Discovery
where he became Commercial Director and drove significant growth of the profitable services busi- ness. Dr Treherne joined Cellesce as Chief Executive in 2018 to help drive the commercialisa- tion of organoids for drug discovery. Dr Treherne has a PhD in Pharmacology from the University of Cambridge.
Dr Marianne Ellis co-founded Cellesce in 2013 based on her extensive knowledge of, and expertise in, tissue engineering bioprocessing for cell thera- pies and in vitro models, particularly scalable bioreactors for cell expansion. She is currently a Senior Lecturer in the Department of Chemical Engineering at the University of Bath and is a char- tered chemical engineer. Dr Ellis has held a Royal Academy of Engineering/Leverhulme Trust Senior Research Fellowship and was recognised as a lead- er of the future with an EPSRC ‘Rising Star’ award in 2014.
Professor Trevor Dale is a pioneering research sci- entist interested in how cells talk to each other, how this goes wrong in cancer – and how protein machines control it all. The main focus of Professor Dale’s research group is on the Wnt sig- nalling pathway, and his team are growing normal and tumour organoids from a number of human tissue types. Professor Dale studied Biochemistry at Imperial College before completing a PhD on interferon signal transduction at the Imperial Cancer Research Fund (now Cancer Research UK). Following a postdoctoral fellowship at Baylor College of Medicine in Houston, he established a research group at the Institute of Cancer Research in London in 1991. Trevor is a professor at Cardiff University.
Dr Luned Badder is a postdoctoral researcher at the Breast Cancer Now unit at King’s College London and the Institute of Cancer Research. Dr Badder obtained her BSc degree in Biomedical Science at Cardiff University, prior to completing a PhD, to develop patient-derived 3D organoids for colorectal cancer therapeutics (European Cancer Stem Cell Research Institute and School of Biosciences, Cardiff University). Dr Badder is an NC3Rs-funded postdoctoral researcher currently focused on deriving 3D organoid models of Triple Negative Breast cancers.
Dr Andrew Hollins is a postdoctoral researcher at Cardiff University with Professor Dale’s research team. Dr Hollins obtained his BSc degree in Biomedical Science at Cardiff University, prior to
Drug Discovery World Winter 2018/19 13
completing a PhD in Pharmaceutical Cell Biology based upon a patient-derived model of lung cell differentiation (Welsh School of Pharmacy, Cardiff University; 2001). Dr Hollins has since further broadened his experience with primary cell culture protocol development across a number of human tissues (including colorectal, lung, liver, mammary, prostate and retinal) and is currently an Innovate UK-funded postdoctoral researcher focused on the development of a scalable breast tumour 3D organoid platform.
References 1Wright et al (1957). New England Journal of Medicine, 257: 1207-11. 2Vlachogiannis et al (2018). Science, 359: 920-26. 3 Paul et al (2010). Nature Reviews Drug Discovery, 9: 203-214. 4 Harris et al (2011). Combinatorial Chemistry & HTS, 14: 521-531. 5 Cohen and Tcherpakov (2010). Cell 143(5): 686-93. 6 Sato et al (2009). Nature, 459(7244): 262-5. 7 Ellis et al. Patent filed July 2016 & published January 2018, WO 2018/011558.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
